Company news

Delcath Systems, Inc. news in 2025

Delcath Systems, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

December 31, 2025

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

December 3, 2025

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

November 20, 2025

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

November 18, 2025

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

November 13, 2025

Delcath Systems to Participate in Upcoming Investor Conferences

November 6, 2025

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

November 4, 2025

Delcath Systems to Host Third Quarter 2025 Earnings Call

October 21, 2025

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

October 18, 2025

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

October 18, 2025

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

September 22, 2025

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

August 19, 2025

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

August 6, 2025

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

July 29, 2025

Delcath Systems to Host Second Quarter 2025 Earnings Call

July 23, 2025

Delcath Systems Issues Full Year 2025 Guidance

May 22, 2025

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 15, 2025

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9, 2025

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

May 8, 2025

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

April 28, 2025

Delcath Systems to Host First Quarter 2025 Earnings Call

April 24, 2025

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

April 9, 2025

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

March 24, 2025

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 14, 2025

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

March 6, 2025

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

February 20, 2025

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

February 13, 2025

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

January 12, 2025

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 2, 2025

Calls in 2025

Decks in 2025